REMEDI and Creganna-Tactx Medical are working on developing next generation solutions for delivery of stem cell therapies.
Orbsen Therapeutics Limited aims to become a leading company in the development of regenerative medicine therapies across a range of diseases and medical conditions.
REMEDI's major industrial healthcare cooperation is with Medtronic Inc., a world leader in medical device technologies. REMEDI and Medtronic have partnered since 2004 to identify and develop new treatments for vascular diseases.
Ovagen are working with REMEDI in a number of areas including using their germ free chicken technology to develop recombinant proteins for regenerative medicine applications.
REMEDI and Ziel Biopharma are co-developing methods for enhancing stem cell efficacy using a unique encapsulation method.
REMEDI in partnership with Smith & Nephew is developing new therapies using adult bone marrow stem cells to promote the re-growth of healthy cartilage and repair damaged joints.
REMEDI has commenced a collaboration with EnBIO developing medical devices and implants with enhanced properties.
Proxy Biomedical and REMEDI have started an exciting collaboration to develop new treatments for osteoarthritis using novel tissue engineering approaches.
Two GTI students, Séan and Gearóid Reily, visited REMEDI as part of their week long immersion into science and technology at NUIG.